You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Noninvasive System for Detection of Sleep Apnea in Animals

    SBC: NEOGENE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The long term goal of this project is to develop and commercialize noninvasive equipment, called the sleep and respiratory track (SARTrak) system, for high throughput detection of sleep apnea in animals. The specific goal for the Phase I application is to design and evaluate a basic model of the SARTrak system with eight chambers (one chamber per animal), i.e. ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A Synthetic Human Cytomegalovirus Vaccine Platform

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish persistent infection in sero-positive individuals. The resulting synthetic product will form the basis for the development of attenuated HCMV vaccines. Innovative synthetic biology methods will overcome ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Intelligent and Automatic Image Segmentation Software for High ThroughputAnalysi

    SBC: CytoInformatics LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): It is well established that aging and many chronic diseases, such as cancer and heart failure, are associated with significant losses in skeletal muscle mass and strength in humans. There is agreement across the musclebiology community that important morphological characteristics of muscle fibers, such as fiber area, the number and position of myonuclei, cellul ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk

    SBC: ZENAGENE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Early Warning system for detecting pre-eclampsia

    SBC: CONVERGENT ENGINEERING, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. human Microvessel Culture System (hMCS)

    SBC: ANGIOMICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing ev ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Nogo Decoy Receptor Therapy for the Treatment of Glaucoma

    SBC: RENETX BIO, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): The objective of this phase I STTR application is to continue assessment of the relevance and feasibility of Nogo decoy receptor therapy for the treatment of glaucoma. The secondary objective is to obtain pharmacokinetic data important for designing additional preclinical efficacy studies and formulating a drug development plan for glaucoma. Our long term objec ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government